{"id":"W2773179393","doi":"10.3899/jrheum.170429","title":"Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Psoriatic arthritis; Erythema; Adverse effect; Placebo; Internal medicine; Rheumatology; Adalimumab; Psoriasis; Population; Arthritis; Surgery; Dermatology; Secukinumab; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003537469,0.000878586,0.001539257,0.000198882,0.0003250693,0.000593936,0.0005636197,0.0007093624,0.002161043],"category_scores_gemma":[0.001294981,0.0003721394,0.001398889,0.0002330761,0.0005137559,0.0005377149,0.0003624166,0.001908205,0.0005905452],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003831634,"about_ca_system_score_gemma":0.0008914626,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004013729,"about_ca_topic_score_gemma":0.0006909677,"domain_scores_codex":[0.9992723,0.0003775255,0.0000502204,0.000103203,0.00009367993,0.0001030466],"domain_scores_gemma":[0.9987522,0.000231712,0.0003072892,0.0001465101,0.00008646537,0.0004758567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6919694,0.07812429,0.03101812,0.001008023,0.002619634,0.000267442,0.000407862,0.00172187,0.04604892,0.0001047173,0.003239651,0.1434701],"study_design_scores_gemma":[0.4690307,0.4631436,0.06160839,0.00004995086,0.0008647894,0.0003067823,0.00005589629,0.0007349143,0.002600623,0.00007593396,0.001499335,0.00002898802],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964989,0.001204472,0.0003656405,0.0001491392,0.00003057219,0.0007393011,0.0003915984,0.00004442691,0.0005759716],"genre_scores_gemma":[0.9936127,0.0009715123,0.001351524,0.0005944399,0.00009962465,0.0008884132,0.001531913,0.00002065295,0.0009292736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003537469,"threshold_uncertainty_score":0.01870817,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01458484954283755,"score_gpt":0.2830322336540225,"score_spread":0.268447384111185,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}